Biotrial names new Managing Director for its Central ECG and Imaging Laboratory

Share Article

Biotrial, a leading CRO for early phase clinical trials, reaches a new step in the development of its Central ECG and Imaging Laboratory and names Philippe L'Hostis to manage the overall direction of both activities.

Biotrial has reorganized and has appointed Philippe L'Hostis Managing Director of its ECG and Imaging Central Laboratory to answer the exponential growth of its business in these areas.

Biotrial ( provides an integrated solution for collecting, managing, and analysing cardiac safety as well as medical imaging data. Its unique IFA Commitment: Integrity of data delivered, Flexibility of the organization and Adaptability to the ever changing technological and regulatory environment, has made Biotrial an increasingly recognized name in this field.

Mr. L'Hostis holds a Master's Degree in Statistical and Numerical Engineering and has been with Biotrial for over 10 years. Prior to this new role he was responsible of the data management department. This position will now be held by Monique Duguépéroux-Klocke, who brings 15 years of experience to the company. Mr L'Hostis will devote 100% of his time to answer the constant growth of this area, ensuring continuous strengthening of the organization with added experienced staff, new technologies and strong validations.

"Over the years Biotrial has developed an extensive experience in QT studies and is today recognized as one of the main worldwide experts in this area," said Mr. L'Hostis. "It is natural that our customers who are happy with our work in QT studies, within our top-of-the-line Phase I facilities, also ask us, more and more, to monitor QT studies which have been performed outside Biotrial. In 2009, our full-service ECG Central Lab - which includes Phase II and III studies, is expected to double its activities. Another factor leading to our success is the result of a close collaboration with our university partners with whom we are currently developing new methods of analysis and signal processing."

Jean-Marc Gandon, Biotrial CEO, commented: "Philippe and I share the same vision for our central laboratory. His wealth of experience in this area will be of enormous benefit for managing our constant growth. Collaborating today with over 15 cardiologists and as many medical imaging experts, Biotrial has built over the years not just a strong organization with enormous experience but also a very strong team that brings unmatched expertise."

The company will be showcasing its services and IFA Commitment from October 28-31, 2008 in London at the 2nd Annual Safety Pharmacology World Europe event (

About Biotrial
Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial ( is an independent and privately owned CRO.
With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners.

With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Central Labs (ECG, Imaging), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.

For further information please contact Anne Peron at [+33] (0)2 99 599 191 or visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Kinnucan
33 (0)2 99 59 91 91
Email >
Visit website